Biogen (BIIB) Tops Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q3 EPS of $5.19, $0.22 better than the analyst estimate of $4.97. Revenue for the quarter came in at $2.96 billion versus the consensus estimate of $2.91 billion.
Eloctate revenue $131.8 million, est. $131.2 million.
Alprolix revenue $85.2 million, est. $86.2 million.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $300 at Guggenheim
- Personalis, Inc. (PSNL) Misses Q3 EPS by 6c
- CrossAmerica Partners (CAPL) Misses Q3 EPS by 8c
Create E-mail Alert Related Categories
Earnings, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
